https://www.80thatom.com/zh/china-biotech-press-watch/annji-proceeds-with-kennedy%E2%80%99s-rare-disease-p3-us-study 2026-10-05 https://www.80thatom.com/zh/china-biotech-press-watch/abogen-deal-with-novartis-exceeds-usd7.2bn 2026-10-05 https://www.80thatom.com/zh/china-biotech-press-watch/phrontline-enters-clinic-with-ovarian-cancer-asset 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/dizal-receives-usd600m-from-azn-for-zegfrovy 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/hutchmed-and-partner-azn-file-us-nda-for-combination-lung-cancer-therapy 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/hengrui-strikes-usd2.6bn-deal-with-novo-for-weight-loss-asset 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/innovent-expands-p3-lung-cancer-study 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/iaso-presents-first-in-human-multiple-myeloma-data-from-two-assets 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/ubt-receives-usd9m-milestone-in-novo-diabetes-partnership 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/innocare-strikes-usd3.25bn-research-and-license-deal-with-lilly 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/hansoh%E2%80%99s-hs-10374-meets-primary-endpoints-in-p3-psoriasis 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/boomray-signs-usd900m-radioligand-deal-with-novartis 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/biokin-triggers-usd250m-milestone-in-bms-deal 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/hengrui-receives-go-ahead-on-triplet-of-clinical-trials 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/accro-aims-high-with-p2b-study-in-uc 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/iaso208-car-t-receives-fda-ind-clearance 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/cspc-starts-p2-type-2-diabetes-weight-loss-study 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/chimagen-sells-oncology-trispecific-to-gsk-for-usd750m 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/interim-p3-analysis-of-ivonescimab-shows-meaningful-benefit-in-lung-cancer 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/cms-receives-approval-for-systemic-lupus-product-trial 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/innocare-ind-approved-for-bispecific-for-prostate-cancer 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/adagene-receives-milestone-payment-from-partner-exelixis 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/medilink-lung-cancer-drug-significantly-extends-overall-survival 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/kelun-publishes-p3-data-in-jco 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/positive-p2a-data-on-rifaquizinone-for-periprosthetic-joint-infection 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/adagene-partner-third-arc-selects-first-drug-candiate 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/ocumension-nda-accepted-for-nmpa-review 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/hutchmed-signs-gsk-cancer-deal 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/hansoh-gets-bla-for-cancer-drug 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/cstone-lists-on-hk-connect 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/harbour-biommed-lists-on-hk-connect 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/harbour-partner-advances-asthma-drug 2026-10-02 https://www.80thatom.com/zh/china-biotech-press-watch/transcenta-and-wuxi-biologics-to-commercialse-bioprocessing-tech 2026-10-02